Abbott India Peer Comparison

NSE: ABBOTINDIA | BSE: 500488

₹26,350.00

₹-205.00 (-0.77%)

As on 27-Aug-2026IST

Market cap

₹56,052 Cr

Revenue (TTM)

₹7,004 Cr

P/E Ratio

34.7

P/B Ratio

10.8

Div. Yield

2.5 %

Edit

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Market cap (₹ Cr)	56,052	1,18,603	98,980	98,075	99,821
Revenue (₹ Cr)	7,004	28,592	29,967	33,228	14,738
Net Profit (₹ Cr)	1,614.68	4,492.20	5,551.01	3,169.30	2,055.11
Net Margin (%)	22.13	14.92	18.23	9.15	13.64
RoE (%)	36.76	18.78	28.32	8.72	13.60
Price to Earnings	34.71	26.28	17.90	30.44	48.87
Price-To-Book	10.83	4.40	4.16	2.57	5.93

Income Statement (₹ Cr)

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Operating Revenue	6,929.05	27,148.40	27,958.03	33,700.20	14,277.64
Total Income	7,219.28	28,943.00	29,038.95	35,058.60	14,636.43
Total Expenditure	5,039.06	19,958.40	19,798.50	27,246.70	10,655.26
EBITDA	1,889.99	7,190.00	8,159.53	6,453.50	3,622.38
Depreciation	75.96	1,408.00	1,375.50	2,058.80	886.18
EBIT	1,814.03	5,782.00	6,784.03	4,394.70	2,736.20
Interest	24.99	438.90	434.49	373.80	644.25
Other Income	290.23	1,794.60	1,080.92	1,358.40	358.79
Exceptional Items	--	-516.60	-557.91	--	-129.75
Profit before Tax	2,079.27	6,621.10	6,872.55	5,392.70	2,332.68
Provision for Tax	527.25	1,594.70	1,517.08	1,235.10	394.58
Profit after Tax	1,552.02	5,026.40	5,355.47	4,157.60	1,938.10

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Shareholder's Funds	4,774.19	27,111.40	22,448.27	37,891.50	16,300.34
Minority Interest	--	2,470.80	65.10	339.40	260.71
Non-Current Liabilities	225.20	5,003.90	2,635.50	926.10	4,686.53
Current Liabilities	1,476.57	15,711.90	12,651.24	16,747.40	6,507.25
Total Liabilities	6,501.93	50,672.60	38,146.06	56,576.70	27,754.83

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Non-Current Assets	2,705.27	30,391.90	13,772.73	25,875.60	20,800.63
Current Assets	3,770.69	19,906.10	24,027.38	30,028.80	6,951.50
Total Assets	6,501.93	50,672.60	38,146.06	56,576.70	27,754.83
Total Debt*	0.00	11,769.50	5,910.20	7,734.10	6,021.78
Net Current Assets	2,294.12	4,194.20	11,376.14	13,281.40	444.25
Contingent Liabilities	114.18	989.90	1,094.02	336.14	924.77

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Cash From Operating Activities	1,319.24	2,116.60	7,334.50	5,673.70	3,121.29
Cash Flow from Investing Activities	-371.38	-8,296.10	-3,864.59	-6,549.30	-196.42
Cash from Financing Activities	-1,066.12	5,806.90	-845.87	829.00	-2,952.69
Net Cash Inflow / Outflow	-118.26	-372.60	2,624.04	-46.60	-27.82

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
ROCE (%)	46.72	21.39	28.86	13.75	13.24
ROE (%)	34.67	19.69	27.11	11.69	12.69
ROA (%)	25.08	11.81	16.12	8.03	7.00
EBIT Margin (%)	31.46	33.09	33.05	23.18	27.88
Net Margin (%)	21.50	17.37	18.44	11.86	13.24
Cash Profit Margin (%)	22.95	12.45	15.61	18.45	18.91

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Revenue Growth (%)	8.11	16.81	23.12	3.24	16.96
EBIT Growth (%)	10.66	22.19	68.65	-19.00	11.92
Net Profit Growth (%)	9.73	8.92	61.98	-27.38	-3.41
EPS Growth (%)	9.73	11.37	62.29	-25.89	-3.97
Book Value Growth (%)	12.93	13.19	30.75	12.99	13.74

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Price / Earnings	35.49	17.39	19.83	24.97	43.29
Price / Book Value	11.60	3.23	4.72	2.78	5.09
Dividend Yield (%)	2.53	0.11	0.78	0.64	0.05
EV/EBITDA	24.23	10.91	11.47	13.97	22.19
Market Cap (₹ Cr)	55,086.64	87,643.18	1,05,737.27	1,04,763.81	82,801.75

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Debt to Equity	0.00	0.43	0.26	0.20	0.37
Short term debt to equity ratio	--	0.16	0.18	0.16	0.04
Current Ratio	2.55	1.27	1.90	1.79	1.07
Quick Ratio	1.91	0.91	1.42	1.34	0.74
Interest Coverage	84.20	16.09	16.82	15.43	4.62

	Abbott India	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Debtors to sales (%)	5.22	19.95	23.62	30.04	12.11
Asset Turnover	1.15	1.21	1.30	0.65	0.54
Receivable days	19.09	33.55	51.23	103.79	39.93
Inventory Days	47.06	33.80	48.93	79.94	51.78
Payable days	106.98	149.82	205.75	84.78	111.46
Cash Conversion Cycle	-40.83	-82.46	-105.59	98.95	-19.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.